BRAF and melanoma: The plasmatic levels of other ncRNAs such as lncRNAs (IGF2AS, anti-Peg11, MEG3, Zeb2NAT) were also found to be associated with prognosis and therapy response in BRAF-mutant advanced melanoma patients treated with the BRAF inhibitor vemurafenib [186].